Liu Jin-yi, An Qian, Xu Guan-dong, Lei Wen-dong, Li Ling, Pan Qin-jing, Han Nai-jun, Cheng Shu-jun, Gao Yan-ning
Cancer Institute (Hospital), Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100021, China.
Zhonghua Zhong Liu Za Zhi. 2004 Feb;26(2):75-7.
To evaluate aberrant methylation of the p16 promoter as a useful biomarker of lung cancer.
A modified methylation-specific semi-nested PCR was performed to detect p16 hypermethylation in the matched samples of tumor tissue, blood plasma and sputum derived from 51 cases of lung cancer patients.
Hypermethylation of p16 promoter was demonstrated in 84.3% of the tumor tissues, 70.6% of the blood plasma and 76.5% of the sputum specimens, respectively. Only the patients whose tumor tissues had p16 hypermethylation exhibited aberrant methylation in their plasma and/or sputum specimens. Combining with cytological examination, 92.2% of the patients with lung cancer could be detected by p16 hypermethylation assay in both sputum and plasma samples.
The results indicate that p16 hypermethylation in plasma and sputum identified by semi-nested PCR is a biomarker of lung cancer which can be useful as an auxillary diagnostic parameter.
评估p16启动子异常甲基化作为肺癌有用生物标志物的情况。
采用改良的甲基化特异性半巢式PCR检测51例肺癌患者肿瘤组织、血浆和痰液配对样本中的p16高甲基化。
p16启动子高甲基化分别在84.3%的肿瘤组织、70.6%的血浆和76.5%的痰液标本中得到证实。只有肿瘤组织存在p16高甲基化的患者其血浆和/或痰液标本中出现异常甲基化。结合细胞学检查，通过痰液和血浆样本中的p16高甲基化检测可发现92.2%的肺癌患者。
结果表明，通过半巢式PCR鉴定的血浆和痰液中的p16高甲基化是肺癌的一种生物标志物，可作为辅助诊断参数。
